- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 455/02 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberineAlkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
Patent holdings for IPC class C07D 455/02
Total number of patents in this class: 101
10-year publication summary
|
8
|
4
|
6
|
5
|
11
|
4
|
8
|
4
|
2
|
6
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme LLC | 3736 |
9 |
| Biosplice Therapeutics, Inc. | 160 |
5 |
| Merck Sharp & Dohme Corp. | 2183 |
4 |
| Emergent Product Development Gaithersburg Inc. | 46 |
4 |
| Dice Alpha, Inc. | 28 |
4 |
| Novartis AG | 10251 |
3 |
| F. Hoffmann-La Roche AG | 7819 |
3 |
| Takeda Pharmaceutical Company Limited | 2710 |
3 |
| 55pharma Drug Discovery & Development AG | 3 |
3 |
| Rigel Pharmaceuticals, Inc. | 507 |
3 |
| Techfields Pharma Co., Ltd. | 28 |
3 |
| Guide Therapeutics, LLC | 6 |
3 |
| Bristol-myers Squibb Company | 4751 |
2 |
| Centre National de La Recherche Scientifique | 11026 |
2 |
| The Trustees of Columbia University in the City of New York | 3648 |
2 |
| Genzyme Corporation | 1367 |
2 |
| Incyte Corporation | 1067 |
2 |
| Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | 377 |
2 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 874 |
2 |
| Universite Grenoble Alpes | 776 |
2 |
| Other owners | 38 |